News | January 06, 2022
Margins under pressure; domestic market growth to slow down: Nirmal Bang
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies
Rapid antigen testing provides results in just 15 minutes and the information can help reduce the risk of Covid-19 exposure
G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE
In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc
The Home Healthcare market is expected to be US $ 14.2 by 2025
Given as few as six times per year and demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition
Vakrangee through its Nextgen Kendras and BharatEasy Mobile Superaap will now be able to provide medicines & healthcare services in remote areas of the country
This round of funding will support Fast&Up and Chicnutrix to expand their domestic presence, enhance manufacturing capabilities and accelerate momentum globally
During H1 FY2022, the revenues and operating profit margin (OPM) for ICRA sample set showed sharp improvement aided by volume uptick in Covid-19 and allied tests and also demand traction for non-Covid tests
Subscribe To Our Newsletter & Stay Updated
